YARW (Yarrow Bioscience) PS Ratio: 749.14 (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YARW Yarrow Bioscience Inc YARW
13 GF Score
Price $26.22
View Full Analysis

What is Yarrow Bioscience PS Ratio?

Yarrow Bioscience YARW -2.78% 13 PS Ratio is 749.14 as of Sep. 15, 2026. GuruFocus rates YARW with a GF Score™ of 13/100. Among 940 Biotechnology companies, Yarrow Bioscience ranks worse than 95.21% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Yarrow Bioscience's share price is $26.22. Yarrow Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.04. Hence, Yarrow Bioscience's PS Ratio for today is 749.14.

The historical rank and industry rank for Yarrow Bioscience's PS Ratio or its related term are showing as below:

YARW' s PS Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 802.56
Current: 750.29

During the past 1 years, Yarrow Bioscience's highest PS Ratio was 802.56. The lowest was 0.00. And the median was 0.00.

YARW's PS Ratio is ranked worse than
95.21% of 940 companies
in the Biotechnology industry
Industry Median: 9.33 vs YARW: 750.29

Yarrow Bioscience's Revenue per Sharefor the three months ended in Jun. 2026 was $0.04. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.04.

Back to Basics: PS Ratio


Yarrow Bioscience  (NAS:YARW) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Yarrow Bioscience PS Ratio Related Terms


Yarrow Bioscience PS Ratio Historical Data

* Premium members only.

The historical data trend for Yarrow Bioscience's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience PS Ratio Chart

Yarrow Bioscience Annual Data
Trend Dec25
PS Ratio
0.00

Yarrow Bioscience Quarterly Data
Jun25 Dec25 Mar26 Jun26
PS Ratio 0.00 0.00 0.00 0.00

YARW vs CGTX, RANI, VRCA: PS Ratio Comparison

For the Biotechnology subindustry, Yarrow Bioscience's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yarrow Bioscience PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's PS Ratio distribution charts can be found below:

* The bar in red indicates where Yarrow Bioscience's PS Ratio falls into.


YARW
13GF Score
Yarrow Bioscience Inc YARW
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yarrow Bioscience PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Yarrow Bioscience's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=26.22/0.035
=749.14

Yarrow Bioscience's Share Price of today is $26.22.
Yarrow Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 749.14 mean?
Yarrow Bioscience (YARW) has a PS Ratio of 749.14 as of Sep. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Yarrow Bioscience and its competitors. According to the industry distribution chart, Yarrow Bioscience ranks #895 out of 940 companies in the Biotechnology industry, placing it in the top 95.2%.
Is Yarrow Bioscience's PS Ratio too high?
Yarrow Bioscience's current PS Ratio is 749.14. The Biotechnology industry median PS Ratio is 9.33. Yarrow Bioscience's value of 749.14 is 7929.4% above this industry median. Based on the distribution chart, Yarrow Bioscience ranks #895 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's PS Ratio compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Yarrow Bioscience ranks #895 out of 940 companies for PS Ratio. This places Yarrow Bioscience in the lower half of its industry. The industry median PS Ratio is 9.33. Yarrow Bioscience's value of 749.14 is 7929.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.33, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yarrow Bioscience's current PS Ratio of 749.14 is 7929.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Yarrow Bioscience and its competitors. For the Biotechnology industry, the median PS Ratio is 9.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yarrow Bioscience's current PS Ratio is 749.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current PS Ratio of 749.14. The current PS Ratio is 749.14 and 7929.4% above the Biotechnology industry median of 9.33. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current PS Ratio is 749.14 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yarrow Bioscience Business Description

Address 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score

Get the complete analysis for YARW

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.22
Price